Efficacy of tegafur/uracil plus oral leucovorin therapy for advanced or recurrent colorectal cancer

Akira Kabashima, Yoshihisa Sakaguchi, Keishi Okita, Shinji Yamamura, Yasutomo Ojima, Takashi Nishizaki, Hideya Tashiro, Toshimitsu Matsuzaka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The aim of this study was to evaluate the efficacy of tegafur/uracil (UFT) and oral Leucovorin(UZEL) in patients with advanced or recurrent colorectal cancer. Eight patients were treated with UFT/UZEL therapy as a first-line chemotherapy. UFT(300 mg/m(2)/day) and UZEL (75 mg/body/day) were administered orally for 28 consecutive days followed by a 7-day rest period, and this schedule was repeated every 5 weeks. The mean of treatment courses given to the patients was 7.6. Tumor response was evaluated in 7 patients who had assessable lesions, and the response rate was 86% (6 PR and 1 NC). Adverse reactions of grade 3 were observed in 2 patients (25%), but toxicity did not cause a discontinuance of treatment in any case. The UFT/UZEL therapy was considered to be a promising regimen for advanced or recurrent colorectal cancer from a standpoint of effect, safety and QOL of patients.

Original languageEnglish
Pages (from-to)1935-1938
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume32
Issue number12
Publication statusPublished - Nov 2005

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy of tegafur/uracil plus oral leucovorin therapy for advanced or recurrent colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Kabashima, A., Sakaguchi, Y., Okita, K., Yamamura, S., Ojima, Y., Nishizaki, T., Tashiro, H., & Matsuzaka, T. (2005). Efficacy of tegafur/uracil plus oral leucovorin therapy for advanced or recurrent colorectal cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 32(12), 1935-1938.